Anavex Life Sciences (AVXL)
(Real Time Quote from BATS)
$5.60 USD
-0.04 (-0.71%)
Updated Sep 23, 2024 09:46 AM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Income Statements
Fiscal Year end for Anavex Life Sciences Corp falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 56 | 51 | 42 | 31 | 29 |
Income After Depreciation & Amortization | -56 | -51 | -42 | -31 | -29 |
Non-Operating Income | 8 | 3 | 4 | 5 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -48 | -48 | -38 | -26 | -26 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -48 | -48 | -38 | -26 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -48 | -48 | -38 | -26 | -26 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -56 | -51 | -42 | -31 | -29 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -56 | -51 | -42 | -31 | -29 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 79.79 | 76.91 | 69.80 | 58.20 | 48.91 |
Diluted EPS Before Non-Recurring Items | -0.60 | -0.62 | -0.54 | -0.45 | -0.50 |
Diluted Net EPS (GAAP) | -0.60 | -0.62 | -0.54 | -0.45 | -0.54 |
Fiscal Year end for Anavex Life Sciences Corp falls in the month of September.
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 14.73 | 12.52 | 11.29 | 12.65 | 13.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | -14.73 | -12.52 | -11.29 | -12.65 | -13.53 |
Non-Operating Income | 2.45 | 2.08 | 2.76 | 2.44 | 2.29 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -12.28 | -10.44 | -8.54 | -10.21 | -11.24 |
Income Taxes | -0.07 | 0.11 | 0.09 | -0.06 | 0.04 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -12.21 | -10.55 | -8.62 | -10.15 | -11.28 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -12.21 | -10.55 | -8.62 | -10.15 | -11.28 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 84.54 | 82.46 | 82.08 | 81.97 | 80.88 |
Diluted EPS Before Non-Recurring Items | -0.14 | -0.13 | -0.11 | -0.12 | -0.14 |
Diluted Net EPS (GAAP) | -0.14 | -0.13 | -0.11 | -0.12 | -0.14 |